Mast Cells

Regarding Renee Twombly's article "Couple Lead Quest For New Allergy Drug" [The Scientist, Jan. 7, 1991, page 1], I was glad to read a piece that described the rapid progress currently being made in our understanding of the processes underlying allergic disease. This progress holds out the promise of new treatments for allergy sufferers. However, I would like to point out two errors. First, histamines (sic) do not come in twos or threes. Histamine is a single molecular entity (C5 H9 N3), and,

Written byKim Barrett
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

First, histamines (sic) do not come in twos or threes. Histamine is a single molecular entity (C5 H9 N3), and, although we have many anti histamines, one would no more refer to histamines than to acetylcholines.

Second, although the process of degranulation from some (but not all) mast cells could well be termed explosive in its rapidity and extent, the cells do not "literally explode" when stimulated by antigen. Mast cell mediator release is a highly specific process, signaled by the cross-linking of IgE receptors on the cell surface and transduced by a number of increasingly well-characterized biochemical mechanisms. The cells are not kamikazes, but regranulate to be stimulated again. It is precisely for these reasons that mast cells have provided a valuable model for the study of receptor-linked exocytosis in general.

Sometimes it seems as if mast cells "get no respect" among the more visible circulating players of the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies